Anti-Coagulants - Seychelles

Seychelles

The Anti-Coagulants market in Seychelles is expected to witness a substantial growth in revenue, reaching US$296.20k by the year 2024.
Furthermore, it is projected that the market will continue to expand at an annual growth rate (CAGR 2024-2029) of 7.59%, ultimately leading to a market volume of US$427.10k by 2029.
In terms of global comparison, United States is anticipated to generate the highest revenue in this market, with a staggering amount of US$16,740.00m in 2024.
Seychelles has seen a rise in the demand for novel oral anticoagulants due to their convenience and improved safety profile.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Coagulants in Seychelles has been on the rise in recent years.

Customer preferences: Patients in Seychelles are increasingly opting for Anti-Coagulants as a preventive measure against blood clots. This trend is in line with the global rise in cardiovascular diseases and the growing awareness among patients about the benefits of early intervention.

Trends in the market: The Anti-Coagulants market in Seychelles is dominated by multinational pharmaceutical companies that offer a range of products to cater to the diverse needs of patients. The market is witnessing an increasing demand for newer oral Anti-Coagulants such as Factor Xa inhibitors, which offer several advantages over traditional therapies such as Warfarin. These drugs have a faster onset of action, a lower risk of bleeding, and do not require frequent monitoring.

Local special circumstances: Seychelles is a small island nation with a population of around 100,000 people. The healthcare system in the country is underdeveloped, and there is a shortage of skilled healthcare professionals. This has led to a lack of access to specialized medical care, including Anti-Coagulant therapy. However, the government has taken steps to improve the healthcare infrastructure in the country, and there is an increasing focus on preventive care.

Underlying macroeconomic factors: The economy of Seychelles is heavily dependent on tourism, which has been severely impacted by the COVID-19 pandemic. This has led to a decline in the country's GDP and a decrease in the purchasing power of consumers. However, the government has implemented several measures to support the healthcare sector, including the provision of free Anti-Coagulant therapy to patients with certain medical conditions. This has helped to offset the impact of the pandemic on the Anti-Coagulants market in Seychelles.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.